LYZZ Capital

MojiaBio is a producer of biomanufacturing innovations that aim to improve sustainability. The company, which is dedicated to removing hazardous pollution and excessive energy consumption manufacturing, creates enzyme engineering and biological metabolic pathway engineering platforms to optimize traditional chemical and petroleum production processes.

SUSTAO is a manufacturer of consumables that meet the technical requirements of medical robots.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

OncoMyx Therapeutics, Inc., established in 2018 and based in Phoenix, Arizona, specializes in the development of oncolytic immunotherapies. The company's core focus is the myxoma virus (MYXV), a unique oncolytic virus that targets both hematologic and solid tumors. OncoMyx's innovative approach involves a patented systemic delivery method, enabling the virus to be carried by human leukocytes to tumor cells, thereby stimulating an immune response to fight cancer.

Wugen is a biotechnology company focused on developing innovative off-the-shelf cellular therapies for cancer treatment. The company specializes in natural killer (NK) cell and CAR-T immuno-oncology therapies, utilizing healthy donor cells that are manipulated to enhance their ability to target and eliminate cancer cells. Wugen's proprietary Moneta platform, along with its expertise in genomic engineering, allows for the creation of a new class of memory NK cell therapies aimed at addressing solid tumors, acute myeloid leukemia, and T-cell malignancies. Through its advancements, Wugen seeks to provide effective treatment options for patients facing life-threatening tumors.

Neurelis is a specialty pharmaceutical company based in Encinitas, California, focused on addressing unmet medical needs in epilepsy and the broader central nervous system market. Established in 2007, the company develops and commercializes product candidates utilizing innovative technologies to improve therapeutic benefits and patient care. Neurelis leverages its expertise in neuroscience to enhance drug delivery mechanisms, enabling the effective administration of a wide range of therapeutic agents, including proteins, peptides, and both large and small molecules. Through its differentiated approach, Neurelis aims to provide solutions that significantly improve treatment outcomes for patients suffering from epilepsy and related conditions.

Jumpcode Genomics is a biotechnology company founded in 2016 by Keith Brown in Carlsbad, California. The company specializes in genome technology, focusing on enhancing the performance of sequencing workflows. Its proprietary technology, CRISPRclean, utilizes the CRISPR/Cas system to selectively deplete unwanted nucleic acid molecules from sequencing libraries. This innovation improves detection sensitivity, reduces bias, and simplifies overall workflows while maintaining the integrity of non-targeted sequences. By integrating seamlessly with standard library preparation services, Jumpcode Genomics aims to provide researchers with more effective tools for decoding and addressing complex biological challenges.

Onchilles Pharma is a biotechnology company based in San Diego, California, founded in 2017. The company focuses on the discovery and development of first-in-class biologic therapies specifically designed for cancer treatment. By leveraging innovative research on neutrophil and macrophage biology, Onchilles Pharma aims to create next-generation immunotherapies that selectively target cancer cells while sparing normal cells and tissues. This approach not only enhances the efficacy of cancer treatment but also minimizes toxicity, providing medical professionals with effective options to treat patients suffering from cancer.

Beijing Mabworks Biotech, a gene engineering mAb company. Mabworks is working on ZMapp, an Ebola treatment developed by San Diego's MAPP Biopharma. It also is developing two clinical stage drug candidates: MIL60, a biosimilar to Genentech's Avastin, and MIL62, a proposed treatment for chronic lymphocytic leukemia.

Qpex Biopharma is a San Diego-based biopharmaceutical company founded in 2018, focused on developing innovative therapies to address the growing challenge of antimicrobial resistance. The company specializes in creating a pipeline of antibiotic drugs aimed at treating infectious diseases in both inpatient and outpatient settings. With a strong emphasis on the discovery, development, and regulatory approval of anti-infective medicines, Qpex Biopharma leverages its expertise and experience in collaboration with public and private partnerships to meet critical medical needs. The company's mission is to provide effective solutions for healthcare professionals facing the complexities of resistant infections, thereby enhancing treatment options for patients.

Alpha Biopharma Inc. is a biopharmaceutical company based in Huangpu, China, focused on researching and developing innovative therapeutics. The company is primarily engaged in the clinical development of AZD3759, a small molecule tyrosine kinase inhibitor designed to treat patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) who have central nervous system metastases. Alpha Biopharma collaborates with prominent international pharmaceutical companies and utilizes a strong scientific consulting and management team to ensure rigorous research and development processes. The company emphasizes a multi-faceted approach to drug development, which includes research, market strategy, and intellectual property protection, while working closely with leading contract research organizations, contract manufacturing organizations, hospitals, and institutes to facilitate the orderly implementation of its projects.

NewMed Medical is a Shanghai-based medical device supplier specializing in interventional artificial heart valve systems. Founded in 2015, the company focuses on researching, developing, manufacturing, and marketing products that include artificial heart valves and transcatheter implantation systems. These products are designed to replace diseased mitral valves, simplifying heart valve replacement surgeries, reducing treatment risks, and enabling faster patient recovery while saving surgery expenses.

Neurelis is a specialty pharmaceutical company based in Encinitas, California, focused on addressing unmet medical needs in epilepsy and the broader central nervous system market. Established in 2007, the company develops and commercializes product candidates utilizing innovative technologies to improve therapeutic benefits and patient care. Neurelis leverages its expertise in neuroscience to enhance drug delivery mechanisms, enabling the effective administration of a wide range of therapeutic agents, including proteins, peptides, and both large and small molecules. Through its differentiated approach, Neurelis aims to provide solutions that significantly improve treatment outcomes for patients suffering from epilepsy and related conditions.

Neurelis is a specialty pharmaceutical company based in Encinitas, California, focused on addressing unmet medical needs in epilepsy and the broader central nervous system market. Established in 2007, the company develops and commercializes product candidates utilizing innovative technologies to improve therapeutic benefits and patient care. Neurelis leverages its expertise in neuroscience to enhance drug delivery mechanisms, enabling the effective administration of a wide range of therapeutic agents, including proteins, peptides, and both large and small molecules. Through its differentiated approach, Neurelis aims to provide solutions that significantly improve treatment outcomes for patients suffering from epilepsy and related conditions.

Chipscreen is an integrated biotech company based in Shenzhen, specializing in the discovery and development of novel small molecule pharmaceuticals. Established in 2001 as a Sino-foreign joint venture by a group of esteemed Chinese returnees with significant academic and industrial expertise, the company employs a proprietary chemical genomics-based discovery platform to create a diverse portfolio of clinical and preclinical stage programs across various therapeutic areas. Chipscreen emphasizes a science-driven approach to drug discovery, supported by strong capabilities in pipeline development, intellectual property management, and regulatory compliance. The company’s strategy involves generating differentiated drug candidates, which may be developed independently or in collaboration with partners throughout the research, preclinical, and clinical stages.